Meet Astherna at Bio-Europe 2025
The Astherna team will be attending BIO-EUROPE® 2025 in Vienna from November 3–5! We are…
Join Prof. Rob Collin at OTS 2025 — retinal ASO therapies
Our CEO and co-founder, Prof. Rob Collin, will be taking the stage at the Oligonucleotide Therapeutics Society…
Alice Randon begins PhD on AMD therapies at Astherna!
Alice joined us as a PhD candidate through the prestigious Marie Skłodowska-Curie Actions (MSCA) Doctoral Network…
Dr. Kaltak presents USH2A exon skipping strategy at USH2025
On Friday, June 20, our Chief Scientific Officer, Dr. Melita Kaltak, will be speaking at…
Dr. Erwin van Wijk shares Usher research insights at Kalorama
Tomorrow, our Head of Preclinical Development, Dr. Erwin van Wijk, will visit Kalorama, a care…
See you at the USH2025 Symposium in Nijmegen!
We are looking forward to the USH2025 Symposium that is taking place from June 19–21…
Promising preclinical data for ASTH-A768 now in Communications Medicine
The preclinical data supporting ASTH-A768, one of our most advanced assets, is now available in…
Health~Holland Grant boosts research for ASO therapies
Our team has been awarded a grant from the Top Sector Life Sciences & Health…
Co-founder Carel Hoyng honoured with Dutch Medical Retina Award
Today, our co-founder, Prof. dr. Carel Hoyng, will be giving a special talk at the…
Leadership transition that continues driving our mission
Our CEO, Berno Maaswinkel, will be stepping down as he faces personal circumstances that make…